# A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Source: https://onco.cc/trials/nct06007690/  
OnCo record `nct06007690` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bel-sar in uveal melanoma, run by Aura Biosciences, active and no longer recruiting.

## Summary

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma is a phase 3 interventional study registered as NCT06007690 by Aura Biosciences, with 108 participants enrolled, started 2023-12-06 and due to reach its primary completion in 2027-11-15. Interventions recorded: Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser and Sham Microinjector.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06007690
- Phase: 3
- Setting: A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
- Sponsor: Aura Biosciences
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT06007690: https://clinicaltrials.gov/study/NCT06007690

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- companies: [Aura Biosciences](https://onco.cc/companies/aura-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06007690.json